Evercore ISI downgraded Bellus Health (BLU) to In Line from Outperform with a price target of $14.75, down from $24, after the company agreed to a deal to be acquired by GSK (GSK).
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BLU: